Blood clot marker may predict immunotherapy success in advanced skin cancer
NCT ID NCT07684066
First seen Jul 06, 2026 · Last updated Jul 23, 2026 · Updated 3 times
Summary
This study looks at whether a routine blood test measuring D-dimer levels can predict if the immunotherapy drug cemiplimab will control advanced cutaneous squamous cell carcinoma. Researchers will follow 116 patients starting cemiplimab in regular care, comparing disease control rates between those with high versus low D-dimer levels. No extra treatments or tests are required beyond standard care. If validated, this simple marker could help personalize treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If D-dimer levels reliably predict treatment response, doctors could tailor cemiplimab therapy for advanced skin cancer patients, avoiding ineffective treatment.
- What could go wrong
- This is an observational study, not a treatment trial. The D-dimer test may not prove useful in real-world settings, and results may not change patient outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Elbe Klinikum Buxtehude
Buxtehude, 21614, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hannover Medical School
Hanover, 30625, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Johannes Wesling Klinikum Minden
Minden, 32429, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Klinikum Bremerhaven Reinkenheide
Bremerhaven, 27574, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University Medical Center Erlangen
Erlangen, 91054, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University Medical Center Göttingen
Göttingen, 37075, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University Medical Center Hamburg-Eppendorf
Hamburg, 20246, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University Medical Center Mainz
Mainz, 55131, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University Medical Center Mannheim
Mannheim, 68167, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University Medical Center OWL, Campus Klinikum Bielefeld Rosenhöhe
Bielefeld, 33647, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University Medical Center Rostock
Rostock, 18057, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University Medical Center Salzburg
Salzburg, 5020, Austria
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University Medical Center Schleswig-Holstein, Campus Kiel
Kiel, 24105, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University Medical Center Schleswig-Holstein, Campus Lübeck
Lübeck, 23538, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University Medical Center Tübingen
Tübingen, 72076, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immunotherapy may treat skin cancer in kidney transplant patients without rejection
- New drug aims to fight skin cancer in transplant patients
- Could a 2-Week radiation course replace longer treatment for skin cancer?
- French study tracks Real-World skin cancer care for 1500 patients
- New drug KUP-101A enters first human tests for advanced skin cancers
- Radiation or watchful waiting? new trial for aggressive skin cancer